Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.

Fiche du document

Type de document
Périmètre
Langue
Identifiant
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/nop/npy051

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31386080

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2054-2577

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_075881197C029

Licences

info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/




Citer ce document

A. Darlix et al., « Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. », Serveur académique Lausannois, ID : 10.1093/nop/npy051


Métriques


Partage / Export

Résumé 0

Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial. An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients. The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression. The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en